Article

Key clinical point: Heavy alcohol intake and ALDH2 rs671 polymorphism are associated with a significantly increased risk for hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)-related cirrhosis.

Major finding: Alcohol intake amount (>160 vs 80-160 g/day: adjusted hazard ratio [aHR] 1.78; P  =  .04) and ALDH2 rs671 polymorphism (GA/AA vs GG genotype: aHR 5.61; P < .001) were significantly associated with an increased incidence of HCC.

Study details: This retrospective cohort study enrolled 1515 patients with cirrhosis due to heavy alcoholism or HBV infection.

Disclosures: This study was sponsored by the Ministry of Science and Technology, Taiwan, E-Da Hospital-National Taiwan University Hospital Joint Research Program, and others.

Source: Tsai MC et al. Association of heavy alcohol intake and ALDH2 rs671 polymorphism with hepatocellular carcinoma and mortality in patients with hepatitis B virus–related cirrhosis. JAMA Netw Open. 2022;5(7):e2223511 (Jul 25). Doi: 10.1001/jamanetworkopen.2022.23511

Key clinical point: Heavy alcohol intake and ALDH2 rs671 polymorphism are associated with a significantly increased risk for hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)-related cirrhosis.

Major finding: Alcohol intake amount (>160 vs 80-160 g/day: adjusted hazard ratio [aHR] 1.78; P  =  .04) and ALDH2 rs671 polymorphism (GA/AA vs GG genotype: aHR 5.61; P < .001) were significantly associated with an increased incidence of HCC.

Study details: This retrospective cohort study enrolled 1515 patients with cirrhosis due to heavy alcoholism or HBV infection.

Disclosures: This study was sponsored by the Ministry of Science and Technology, Taiwan, E-Da Hospital-National Taiwan University Hospital Joint Research Program, and others.

Source: Tsai MC et al. Association of heavy alcohol intake and ALDH2 rs671 polymorphism with hepatocellular carcinoma and mortality in patients with hepatitis B virus–related cirrhosis. JAMA Netw Open. 2022;5(7):e2223511 (Jul 25). Doi: 10.1001/jamanetworkopen.2022.23511

Key clinical point: Heavy alcohol intake and ALDH2 rs671 polymorphism are associated with a significantly increased risk for hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)-related cirrhosis.

Major finding: Alcohol intake amount (>160 vs 80-160 g/day: adjusted hazard ratio [aHR] 1.78; P  =  .04) and ALDH2 rs671 polymorphism (GA/AA vs GG genotype: aHR 5.61; P < .001) were significantly associated with an increased incidence of HCC.

Study details: This retrospective cohort study enrolled 1515 patients with cirrhosis due to heavy alcoholism or HBV infection.

Disclosures: This study was sponsored by the Ministry of Science and Technology, Taiwan, E-Da Hospital-National Taiwan University Hospital Joint Research Program, and others.

Source: Tsai MC et al. Association of heavy alcohol intake and ALDH2 rs671 polymorphism with hepatocellular carcinoma and mortality in patients with hepatitis B virus–related cirrhosis. JAMA Netw Open. 2022;5(7):e2223511 (Jul 25). Doi: 10.1001/jamanetworkopen.2022.23511

Key clinical point: The excellent 10-year post-liver transplant (LT) outcomes in patients with hepatocellular carcinoma (HCC) successfully downstaged to within Milan criteria (MC) substantiate the validity of the national downstaging policy.

Major finding: At 10 years after LT, patients with HCC always within MC, those with HCC downstaged before LT, and those with HCC unsuccessfully downstaged/progressed beyond MC during LT had survival rates of 61.5%, 52.1%, and 43.3%, respectively, and recurrence rates of 13.3%, 20.6%, and 41.4%, respectively.

Study details: This retrospective cohort study analyzed the prospective data of 2645 adult patients with HCC who underwent LT at 5 US academic centers.

Disclosures: This study was sponsored by the US Department of Defense, Samuel Waxman Cancer Research Foundation, Spanish National Health Institute, and Cancer Research UK, among others. Two authors reported receiving grants or a board of directors’ honoraria from various sources.

Source: Tabrizian P et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2800

Key clinical point: The excellent 10-year post-liver transplant (LT) outcomes in patients with hepatocellular carcinoma (HCC) successfully downstaged to within Milan criteria (MC) substantiate the validity of the national downstaging policy.

Major finding: At 10 years after LT, patients with HCC always within MC, those with HCC downstaged before LT, and those with HCC unsuccessfully downstaged/progressed beyond MC during LT had survival rates of 61.5%, 52.1%, and 43.3%, respectively, and recurrence rates of 13.3%, 20.6%, and 41.4%, respectively.

Study details: This retrospective cohort study analyzed the prospective data of 2645 adult patients with HCC who underwent LT at 5 US academic centers.

Disclosures: This study was sponsored by the US Department of Defense, Samuel Waxman Cancer Research Foundation, Spanish National Health Institute, and Cancer Research UK, among others. Two authors reported receiving grants or a board of directors’ honoraria from various sources.

Source: Tabrizian P et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2800

Key clinical point: The excellent 10-year post-liver transplant (LT) outcomes in patients with hepatocellular carcinoma (HCC) successfully downstaged to within Milan criteria (MC) substantiate the validity of the national downstaging policy.

Major finding: At 10 years after LT, patients with HCC always within MC, those with HCC downstaged before LT, and those with HCC unsuccessfully downstaged/progressed beyond MC during LT had survival rates of 61.5%, 52.1%, and 43.3%, respectively, and recurrence rates of 13.3%, 20.6%, and 41.4%, respectively.

Study details: This retrospective cohort study analyzed the prospective data of 2645 adult patients with HCC who underwent LT at 5 US academic centers.

Disclosures: This study was sponsored by the US Department of Defense, Samuel Waxman Cancer Research Foundation, Spanish National Health Institute, and Cancer Research UK, among others. Two authors reported receiving grants or a board of directors’ honoraria from various sources.

Source: Tabrizian P et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2800

Key clinical point: Lenvatinib combined with transarterial chemoembolization (LEN-TACE) is more effective than LEN alone as the first-line therapy for advanced hepatocellular carcinoma (HCC).

Major finding: After a 17.0-month median follow-up, the LEN-TACE vs LEN group had a significantly longer median overall survival (17.8 vs 11.5 months; hazard ratio [HR] 0.45; P < .001) and progression-free survival (10.6 vs 6.4 months; HR 0.43; P < .001) and higher objective response rate (54.1% vs 25.0%; P < .001).

Study details: Findings are from a multicenter, phase 3 trial, LAUNCH, that included 338 adult patients with treatment-naive primary or initial recurrent advanced HCC after surgery who were randomly assigned to receive LEN-TACE (n = 170) or LEN monotherapy (n = 168).

Disclosures: This study was supported by Science and Technology Innovation 2030 Major Projects, China, among others. One author declared serving as a consultant/advisor for and receiving honoraria and research funding from GenomiCare.

Source: Peng Z et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2022 (Aug 3). Doi: 10.1200/JCO.22.00392

Key clinical point: Lenvatinib combined with transarterial chemoembolization (LEN-TACE) is more effective than LEN alone as the first-line therapy for advanced hepatocellular carcinoma (HCC).

Major finding: After a 17.0-month median follow-up, the LEN-TACE vs LEN group had a significantly longer median overall survival (17.8 vs 11.5 months; hazard ratio [HR] 0.45; P < .001) and progression-free survival (10.6 vs 6.4 months; HR 0.43; P < .001) and higher objective response rate (54.1% vs 25.0%; P < .001).

Study details: Findings are from a multicenter, phase 3 trial, LAUNCH, that included 338 adult patients with treatment-naive primary or initial recurrent advanced HCC after surgery who were randomly assigned to receive LEN-TACE (n = 170) or LEN monotherapy (n = 168).

Disclosures: This study was supported by Science and Technology Innovation 2030 Major Projects, China, among others. One author declared serving as a consultant/advisor for and receiving honoraria and research funding from GenomiCare.

Source: Peng Z et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2022 (Aug 3). Doi: 10.1200/JCO.22.00392

Key clinical point: Lenvatinib combined with transarterial chemoembolization (LEN-TACE) is more effective than LEN alone as the first-line therapy for advanced hepatocellular carcinoma (HCC).

Major finding: After a 17.0-month median follow-up, the LEN-TACE vs LEN group had a significantly longer median overall survival (17.8 vs 11.5 months; hazard ratio [HR] 0.45; P < .001) and progression-free survival (10.6 vs 6.4 months; HR 0.43; P < .001) and higher objective response rate (54.1% vs 25.0%; P < .001).

Study details: Findings are from a multicenter, phase 3 trial, LAUNCH, that included 338 adult patients with treatment-naive primary or initial recurrent advanced HCC after surgery who were randomly assigned to receive LEN-TACE (n = 170) or LEN monotherapy (n = 168).

Disclosures: This study was supported by Science and Technology Innovation 2030 Major Projects, China, among others. One author declared serving as a consultant/advisor for and receiving honoraria and research funding from GenomiCare.

Source: Peng Z et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2022 (Aug 3). Doi: 10.1200/JCO.22.00392

Key clinical point: Gastrointestinal (GI)‐specific anxiety was the strongest contributor to reduced quality of life (QoL) in patients with irritable bowel syndrome (IBS).

Major finding: The factors independently associated with reduced IBS-QoL were a higher stool frequency (β −0.109; P  =  .022), GI (β −0.160; P  =  .009) and overall somatic symptom severity (β −0.171; P  =  .005), and psychological distress (β −0.194; P  =  .011), with GI‐specific anxiety (β −0.330; P < .001) being the strongest contributor.

Study details: This study included 314 patients with IBS from 2 prospective cohorts who completed the IBS-QoL and self‐report symptom questionnaires and tests for the measurement of oroanal transit time and rectal sensitivity.

Disclosures: This study was funded by Swedish state under the agreement between the Swedish government and the county councils (the ALF‐agreement) and others. Some authors declared serving as consultants/advisory board members or on speakers’ bureau for various sources.

Source: Melchior C et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 (Jul 13). Doi: 10.1002/ueg2.12277

Key clinical point: Gastrointestinal (GI)‐specific anxiety was the strongest contributor to reduced quality of life (QoL) in patients with irritable bowel syndrome (IBS).

Major finding: The factors independently associated with reduced IBS-QoL were a higher stool frequency (β −0.109; P  =  .022), GI (β −0.160; P  =  .009) and overall somatic symptom severity (β −0.171; P  =  .005), and psychological distress (β −0.194; P  =  .011), with GI‐specific anxiety (β −0.330; P < .001) being the strongest contributor.

Study details: This study included 314 patients with IBS from 2 prospective cohorts who completed the IBS-QoL and self‐report symptom questionnaires and tests for the measurement of oroanal transit time and rectal sensitivity.

Disclosures: This study was funded by Swedish state under the agreement between the Swedish government and the county councils (the ALF‐agreement) and others. Some authors declared serving as consultants/advisory board members or on speakers’ bureau for various sources.

Source: Melchior C et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 (Jul 13). Doi: 10.1002/ueg2.12277

Key clinical point: Gastrointestinal (GI)‐specific anxiety was the strongest contributor to reduced quality of life (QoL) in patients with irritable bowel syndrome (IBS).

Major finding: The factors independently associated with reduced IBS-QoL were a higher stool frequency (β −0.109; P  =  .022), GI (β −0.160; P  =  .009) and overall somatic symptom severity (β −0.171; P  =  .005), and psychological distress (β −0.194; P  =  .011), with GI‐specific anxiety (β −0.330; P < .001) being the strongest contributor.

Study details: This study included 314 patients with IBS from 2 prospective cohorts who completed the IBS-QoL and self‐report symptom questionnaires and tests for the measurement of oroanal transit time and rectal sensitivity.

Disclosures: This study was funded by Swedish state under the agreement between the Swedish government and the county councils (the ALF‐agreement) and others. Some authors declared serving as consultants/advisory board members or on speakers’ bureau for various sources.

Source: Melchior C et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 (Jul 13). Doi: 10.1002/ueg2.12277

Key clinical point: The colonic microbial environment changes with exacerbation of symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D).

Major finding: The fecal alpha-diversity was significantly different between IBS without vs with symptom exacerbation (P < .01). The transcription levels of genes involved in enzymatic glutamine to tryptophan synthesis, putrescine to GABA synthesis, inositol degradation, menaquinone synthesis, crotonyl-CoA to butyrate synthesis, and propionate synthesis were significantly lower in IBS with vs without symptom exacerbation (P < .05).

Study details: Findings are from an analysis of 43 male patients with IBS-D and 40 healthy male controls.

Disclosures: This study was supported by grants from JSPS KAKENHI, Japan, the Japanese Food Science Institute Foundation, and others. The authors declared no conflicts of interest.

Source: Tanaka Y et al. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J Gastroenterol. 2022 (Jul 30).  Doi: 10.1007/s00535-022-01888-2

Key clinical point: The colonic microbial environment changes with exacerbation of symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D).

Major finding: The fecal alpha-diversity was significantly different between IBS without vs with symptom exacerbation (P < .01). The transcription levels of genes involved in enzymatic glutamine to tryptophan synthesis, putrescine to GABA synthesis, inositol degradation, menaquinone synthesis, crotonyl-CoA to butyrate synthesis, and propionate synthesis were significantly lower in IBS with vs without symptom exacerbation (P < .05).

Study details: Findings are from an analysis of 43 male patients with IBS-D and 40 healthy male controls.

Disclosures: This study was supported by grants from JSPS KAKENHI, Japan, the Japanese Food Science Institute Foundation, and others. The authors declared no conflicts of interest.

Source: Tanaka Y et al. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J Gastroenterol. 2022 (Jul 30).  Doi: 10.1007/s00535-022-01888-2

Key clinical point: The colonic microbial environment changes with exacerbation of symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D).

Major finding: The fecal alpha-diversity was significantly different between IBS without vs with symptom exacerbation (P < .01). The transcription levels of genes involved in enzymatic glutamine to tryptophan synthesis, putrescine to GABA synthesis, inositol degradation, menaquinone synthesis, crotonyl-CoA to butyrate synthesis, and propionate synthesis were significantly lower in IBS with vs without symptom exacerbation (P < .05).

Study details: Findings are from an analysis of 43 male patients with IBS-D and 40 healthy male controls.

Disclosures: This study was supported by grants from JSPS KAKENHI, Japan, the Japanese Food Science Institute Foundation, and others. The authors declared no conflicts of interest.

Source: Tanaka Y et al. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J Gastroenterol. 2022 (Jul 30).  Doi: 10.1007/s00535-022-01888-2

Key clinical point: A starch‐ and sucrose‐reduced diet (SSRD) led to a significant shift in the gut microbiota, which correlated with reduced gastrointestinal (GI) symptoms, in patients with irritable bowel syndrome (IBS).

Major finding: A significant shift in beta-diversity was observed in the intervention group (P < .001), along with a significant increase in the abundance of Proteobacteria (P  =  .0036), Lentisphaerae (P  =  .0038), and Cyanobacteria (P  =  .038) and a decrease in Bacteroidetes (P < .001). The abundance of Proteobacteria correlated positively (P  =  .0016) and Bacteroidetes negatively (P  =  .0017) with reduced total GI symptoms.

Study details: This study included 105 patients with IBS who were randomly assigned to receive a 4‐week SSRD intervention (n = 80) or habitual (n = 25) diet.

Disclosures: This study was partially funded by the Skåne University Hospital Foundation, Dir Albert Påhlsson Foundation, and others. The authors declared no conflicts of interest.

Source: Nilholm C et al. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022;10(4):363-375 (Apr 28). Doi: 10.1002/ueg2.12227

Key clinical point: A starch‐ and sucrose‐reduced diet (SSRD) led to a significant shift in the gut microbiota, which correlated with reduced gastrointestinal (GI) symptoms, in patients with irritable bowel syndrome (IBS).

Major finding: A significant shift in beta-diversity was observed in the intervention group (P < .001), along with a significant increase in the abundance of Proteobacteria (P  =  .0036), Lentisphaerae (P  =  .0038), and Cyanobacteria (P  =  .038) and a decrease in Bacteroidetes (P < .001). The abundance of Proteobacteria correlated positively (P  =  .0016) and Bacteroidetes negatively (P  =  .0017) with reduced total GI symptoms.

Study details: This study included 105 patients with IBS who were randomly assigned to receive a 4‐week SSRD intervention (n = 80) or habitual (n = 25) diet.

Disclosures: This study was partially funded by the Skåne University Hospital Foundation, Dir Albert Påhlsson Foundation, and others. The authors declared no conflicts of interest.

Source: Nilholm C et al. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022;10(4):363-375 (Apr 28). Doi: 10.1002/ueg2.12227

Key clinical point: A starch‐ and sucrose‐reduced diet (SSRD) led to a significant shift in the gut microbiota, which correlated with reduced gastrointestinal (GI) symptoms, in patients with irritable bowel syndrome (IBS).

Major finding: A significant shift in beta-diversity was observed in the intervention group (P < .001), along with a significant increase in the abundance of Proteobacteria (P  =  .0036), Lentisphaerae (P  =  .0038), and Cyanobacteria (P  =  .038) and a decrease in Bacteroidetes (P < .001). The abundance of Proteobacteria correlated positively (P  =  .0016) and Bacteroidetes negatively (P  =  .0017) with reduced total GI symptoms.

Study details: This study included 105 patients with IBS who were randomly assigned to receive a 4‐week SSRD intervention (n = 80) or habitual (n = 25) diet.

Disclosures: This study was partially funded by the Skåne University Hospital Foundation, Dir Albert Påhlsson Foundation, and others. The authors declared no conflicts of interest.

Source: Nilholm C et al. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022;10(4):363-375 (Apr 28). Doi: 10.1002/ueg2.12227

Key clinical point: A diet low in fat and copper and rich in fiber and zinc might benefit patients with comorbid migraine and irritable bowel syndrome (IBS).

Major finding: The frequency of migraine attacks per month and IBS severity scores were positively correlated with dietary intake of fats and copper (all P < .05) and negatively correlated with dietary intake of fibers and zinc (all P < .05).

Study details: Findings are from a cross-sectional study including 100 patients with concomitant migraine and IBS.

Disclosures: This study did not receive any funding, except open access funding provided by The Science, Technology, & Innovation Funding Authority in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Magdy R et al. The potential impact of nutritional intake on symptoms severity in patients with comorbid migraine and irritable bowel syndrome. BMC Neurol. 2022;22:199 (May 30). Doi: 10.1186/s12883-022-02723-0

Key clinical point: A diet low in fat and copper and rich in fiber and zinc might benefit patients with comorbid migraine and irritable bowel syndrome (IBS).

Major finding: The frequency of migraine attacks per month and IBS severity scores were positively correlated with dietary intake of fats and copper (all P < .05) and negatively correlated with dietary intake of fibers and zinc (all P < .05).

Study details: Findings are from a cross-sectional study including 100 patients with concomitant migraine and IBS.

Disclosures: This study did not receive any funding, except open access funding provided by The Science, Technology, & Innovation Funding Authority in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Magdy R et al. The potential impact of nutritional intake on symptoms severity in patients with comorbid migraine and irritable bowel syndrome. BMC Neurol. 2022;22:199 (May 30). Doi: 10.1186/s12883-022-02723-0

Key clinical point: A diet low in fat and copper and rich in fiber and zinc might benefit patients with comorbid migraine and irritable bowel syndrome (IBS).

Major finding: The frequency of migraine attacks per month and IBS severity scores were positively correlated with dietary intake of fats and copper (all P < .05) and negatively correlated with dietary intake of fibers and zinc (all P < .05).

Study details: Findings are from a cross-sectional study including 100 patients with concomitant migraine and IBS.

Disclosures: This study did not receive any funding, except open access funding provided by The Science, Technology, & Innovation Funding Authority in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Magdy R et al. The potential impact of nutritional intake on symptoms severity in patients with comorbid migraine and irritable bowel syndrome. BMC Neurol. 2022;22:199 (May 30). Doi: 10.1186/s12883-022-02723-0

Key clinical point: In patients newly diagnosed with irritable bowel syndrome (IBS), an 8-week fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-lowering diet application was superior to a spasmolytic agent, otilonium bromide (OB), in improving disease symptoms.

Major finding: At 8 weeks, the response rate (71% vs 61%; P  =  .03) and treatment adherence rate (94% vs 73%; P < .001) were significantly higher in the diet vs OB arm, with the improvement in IBS Symptom Severity Score being significantly higher in the diet group (P  =  .02). No serious adverse reactions were recorded.

Study details: Findings are from the DOMINO trial that included 459 primary care patients with IBS who were randomly assigned to the 8-week OB (40 mg, 3 times/day) or FODMAP-lowering diet application group.

Disclosures: This study was funded through the Belgian Health Care Knowledge Centre and others. The authors declared serving as scientific advisors or on speaker bureaus or receiving research support or grants from various sources.

Source: Carbone F et al. Diet or medication in primary care patients with IBS: The DOMINO study - a randomized trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 (Apr 28). Doi: 10.1136/gutjnl-2021-325821

Key clinical point: In patients newly diagnosed with irritable bowel syndrome (IBS), an 8-week fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-lowering diet application was superior to a spasmolytic agent, otilonium bromide (OB), in improving disease symptoms.

Major finding: At 8 weeks, the response rate (71% vs 61%; P  =  .03) and treatment adherence rate (94% vs 73%; P < .001) were significantly higher in the diet vs OB arm, with the improvement in IBS Symptom Severity Score being significantly higher in the diet group (P  =  .02). No serious adverse reactions were recorded.

Study details: Findings are from the DOMINO trial that included 459 primary care patients with IBS who were randomly assigned to the 8-week OB (40 mg, 3 times/day) or FODMAP-lowering diet application group.

Disclosures: This study was funded through the Belgian Health Care Knowledge Centre and others. The authors declared serving as scientific advisors or on speaker bureaus or receiving research support or grants from various sources.

Source: Carbone F et al. Diet or medication in primary care patients with IBS: The DOMINO study - a randomized trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 (Apr 28). Doi: 10.1136/gutjnl-2021-325821

Key clinical point: In patients newly diagnosed with irritable bowel syndrome (IBS), an 8-week fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-lowering diet application was superior to a spasmolytic agent, otilonium bromide (OB), in improving disease symptoms.

Major finding: At 8 weeks, the response rate (71% vs 61%; P  =  .03) and treatment adherence rate (94% vs 73%; P < .001) were significantly higher in the diet vs OB arm, with the improvement in IBS Symptom Severity Score being significantly higher in the diet group (P  =  .02). No serious adverse reactions were recorded.

Study details: Findings are from the DOMINO trial that included 459 primary care patients with IBS who were randomly assigned to the 8-week OB (40 mg, 3 times/day) or FODMAP-lowering diet application group.

Disclosures: This study was funded through the Belgian Health Care Knowledge Centre and others. The authors declared serving as scientific advisors or on speaker bureaus or receiving research support or grants from various sources.

Source: Carbone F et al. Diet or medication in primary care patients with IBS: The DOMINO study - a randomized trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 (Apr 28). Doi: 10.1136/gutjnl-2021-325821

Key clinical point: This meta-analysis demonstrated the superiority of peppermint oil over placebo for improvements in the signs and symptoms of irritable bowel syndrome (IBS); however, adverse events were more frequent with peppermint oil use.

Major finding: Peppermint oil was superior to placebo for global IBS symptoms (relative risk [RR] for persisting global IBS symptoms 0.65; 95% CI 0.43-0.98) and abdominal pain (RR for no improvement in abdominal pain 0.76; 95% CI 0.62-0.93) after therapy. The rate of any adverse events (RR 1.57; 95% CI 1.04-2.37), particularly gastroesophageal reflux symptoms, was higher among patients receiving peppermint oil.

Study details: The data come from a meta-analysis of 10 randomized controlled trials including 1030 patients with IBS, of which 525 were assigned to receive peppermint oil.

Disclosures: This study received no external funding. No conflicts of interest were declared.

Source: Ingrosso MR et al. Systematic review and meta-analysis: Efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022 (Aug 9). Doi: 10.1111/apt.17179

Key clinical point: This meta-analysis demonstrated the superiority of peppermint oil over placebo for improvements in the signs and symptoms of irritable bowel syndrome (IBS); however, adverse events were more frequent with peppermint oil use.

Major finding: Peppermint oil was superior to placebo for global IBS symptoms (relative risk [RR] for persisting global IBS symptoms 0.65; 95% CI 0.43-0.98) and abdominal pain (RR for no improvement in abdominal pain 0.76; 95% CI 0.62-0.93) after therapy. The rate of any adverse events (RR 1.57; 95% CI 1.04-2.37), particularly gastroesophageal reflux symptoms, was higher among patients receiving peppermint oil.

Study details: The data come from a meta-analysis of 10 randomized controlled trials including 1030 patients with IBS, of which 525 were assigned to receive peppermint oil.

Disclosures: This study received no external funding. No conflicts of interest were declared.

Source: Ingrosso MR et al. Systematic review and meta-analysis: Efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022 (Aug 9). Doi: 10.1111/apt.17179

Key clinical point: This meta-analysis demonstrated the superiority of peppermint oil over placebo for improvements in the signs and symptoms of irritable bowel syndrome (IBS); however, adverse events were more frequent with peppermint oil use.

Major finding: Peppermint oil was superior to placebo for global IBS symptoms (relative risk [RR] for persisting global IBS symptoms 0.65; 95% CI 0.43-0.98) and abdominal pain (RR for no improvement in abdominal pain 0.76; 95% CI 0.62-0.93) after therapy. The rate of any adverse events (RR 1.57; 95% CI 1.04-2.37), particularly gastroesophageal reflux symptoms, was higher among patients receiving peppermint oil.

Study details: The data come from a meta-analysis of 10 randomized controlled trials including 1030 patients with IBS, of which 525 were assigned to receive peppermint oil.

Disclosures: This study received no external funding. No conflicts of interest were declared.

Source: Ingrosso MR et al. Systematic review and meta-analysis: Efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022 (Aug 9). Doi: 10.1111/apt.17179

Key clinical point: This meta-analysis found insufficient evidence on the beneficial effects of vitamin D supplementation on irritable bowel syndrome (IBS) symptoms; however, supplementation with vitamin D significantly improved the quality of life (QoL) in patients with IBS.

Major finding: Patients receiving vitamin D supplementation showed a significant improvement in IBS-QoL scores compared with those receiving placebo (mean difference 6.19; P  =  .04). However, IBS-Severity Scoring System scores were not significantly different between the treatment arms.

Study details: The data come from a systematic review and meta-analysis articles of 6 randomized control studies including 616 participants.

Disclosures: This study received no external funding. No conflicts of interest were declared.

Source: Abuelazm M et al. The effect of vitamin D supplementation on the severity of symptoms and the quality of life in irritable bowel syndrome patients: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14(13):2618 (Jun 24). Doi: 10.3390/nu14132618

Key clinical point: This meta-analysis found insufficient evidence on the beneficial effects of vitamin D supplementation on irritable bowel syndrome (IBS) symptoms; however, supplementation with vitamin D significantly improved the quality of life (QoL) in patients with IBS.

Major finding: Patients receiving vitamin D supplementation showed a significant improvement in IBS-QoL scores compared with those receiving placebo (mean difference 6.19; P  =  .04). However, IBS-Severity Scoring System scores were not significantly different between the treatment arms.

Study details: The data come from a systematic review and meta-analysis articles of 6 randomized control studies including 616 participants.

Disclosures: This study received no external funding. No conflicts of interest were declared.

Source: Abuelazm M et al. The effect of vitamin D supplementation on the severity of symptoms and the quality of life in irritable bowel syndrome patients: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14(13):2618 (Jun 24). Doi: 10.3390/nu14132618

Key clinical point: This meta-analysis found insufficient evidence on the beneficial effects of vitamin D supplementation on irritable bowel syndrome (IBS) symptoms; however, supplementation with vitamin D significantly improved the quality of life (QoL) in patients with IBS.

Major finding: Patients receiving vitamin D supplementation showed a significant improvement in IBS-QoL scores compared with those receiving placebo (mean difference 6.19; P  =  .04). However, IBS-Severity Scoring System scores were not significantly different between the treatment arms.

Study details: The data come from a systematic review and meta-analysis articles of 6 randomized control studies including 616 participants.

Disclosures: This study received no external funding. No conflicts of interest were declared.

Source: Abuelazm M et al. The effect of vitamin D supplementation on the severity of symptoms and the quality of life in irritable bowel syndrome patients: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14(13):2618 (Jun 24). Doi: 10.3390/nu14132618